drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An anti-HER2 antibody–drug conjugate (ADC) composed of a humanized anti‑HER2 monoclonal antibody linked to the microtubule inhibitor MMAE (vedotin); upon HER2 binding and internalization, releases MMAE to disrupt microtubules, causing cell-cycle arrest and apoptosis, and may mediate ADCC.
nci_thesaurus_concept_id
C169918
nci_thesaurus_preferred_term
Disitamab Vedotin
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab vedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
drug_mesh_term
disitamab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti‑HER2 monoclonal antibody linked to the microtubule inhibitor MMAE (vedotin). After binding HER2 on tumor cells and internalization, the linker is cleaved to release MMAE, which binds tubulin and inhibits microtubule polymerization, causing G2/M arrest and apoptosis; the IgG1 antibody may also mediate ADCC.
drug_name
Disitamab vedotin
nct_id_drug_ref
NCT06233864